As of 2025-07-01, the Intrinsic Value of Oramed Pharmaceuticals Inc (ORMP) is -3.46 USD. This ORMP valuation is based on the model Peter Lynch Fair Value. With the current market price of 2.10 USD, the upside of Oramed Pharmaceuticals Inc is -264.59%.
Based on its market price of 2.10 USD and our intrinsic valuation, Oramed Pharmaceuticals Inc (ORMP) is overvalued by 264.59%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -3.46 - -3.46 | -3.46 | -264.59% |
| P/E | (13.22) - (12.62) | (13.25) | -731.2% |
| DDM - Stable | (5.39) - (20.95) | (13.17) | -727.2% |
| DDM - Multi | (3.19) - (10.07) | (4.90) | -333.2% |
| Market Cap (mil) | 85.78 |
| Beta | 0.37 |
| Outstanding shares (mil) | 40.85 |
| Enterprise Value (mil) | 11.27 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.97% |
| Cost of Debt | 5.00% |
| WACC | 6.82% |